Michael Seganish
Distinguished Scientist, Discovery Chemistry MSD
Michael has worked at MSD for 17 years in the discovery chemistry group. Over the past 6 years he has focused on building capabilities in ADCs and targeted delivery at the South San Francisco, California site. These efforts have focused on novel ADC targets, novel payloads as well as novel formats including peptide drug conjugates, the results of which have been a rapidly growing preclinical as well as late-stage clinical pipeline of novel ADCs.
Seminars
Understanding the challenges and opportunities at the forefront of ADC conjugation is vital to optimise ADC design, DAR and therapeutic properties capabilities from the get-go
Join this workshop to secure your understanding of fundamental principles of ADC conjugation, assess the pros and cons of next-generation site-specific technologies and explore how best to approach conjugation design with clinical differentiation in mind
Workshop highlights include:
- Delving into ADC bioconjugation: What is the chemistry behind building ADCs?
- Assessing the pros and cons of different conjugation methods across sitespecific and click chemistries, including biorthogonal methods
- Breaking down the foresight and innovation during discovery to maximise differentiated ADC performance in the clinic
